The Role of Granulation Tissue in Periodontal Regeneration

NCT ID: NCT07254117

Last Updated: 2025-11-28

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 46 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-05-29
• Study Completion Date: 2026-09-30

Brief Summary

The goal of this observational study is to distinguish the infectious, healing, and regeneration-related characteristics of two types of gingival granulation tissues, namely infra-osseous and supra-osseous granulation tissues, in people with severe periodontitis (gum disease). Researchers aim to denote if these tissues may play role in healing after periodontal treatment. Researchers will also compare smokers and non-smokers to see if smoking disrupts the healing potential or infectious properties of granulation tissue. Participants will provide gingival fluid (before) and granulation tissue samples (at the time of) periodontal surgery. The main questions this study aims to answer are: 1. Do infra- and supra-osseous granulation tissues have different healing potential and infectious properties? 2. How do these tissues differ in people who smoke compared to people who do not smoke?

Detailed Description

This study aims to investigate the biochemical (tissue healing and regenerative) and microbial (infectious) properties of infra- and supra- osseous granulation tissues and compare those characteristics in non-smoking and smoking periodontitis patients. To accomplish these aims, we designed 3 research objectives: 1. To compare the pro-healing and regenerative properties of infra- and supra-osseous granulation tissues harvested from non-smoking periodontitis patients using open-ended proteomics tools. 2. To describe the infectious component of infra- and supra-osseous granulation tissues harvested from non-smoking periodontitis patients using microbiome analysis. 3. To compare the effect of smoking on selected pro-healing, regenerative and virulence markers of infra-osseous granulation tissues. Our main hypothesis is that infra-osseous and supra-osseous granulation tissues of smokers and non-smokers differ from each other in terms of their pro-healing, regenerative and microbial virulence properties, and infra-osseous granulation tissue is a valuable resource for tissue regeneration after periodontal treatment. The demographics of all individuals will be recorded, and full-mouth visible plaque index (PI%), probing pocket depth (PPD), clinical attachment level (CAL) and bleeding on probing (BoP%) scores from six sites of each tooth will be recorded. Periapical radiographs will be taken. Before the surgical applications, all patients will receive full-mouth scaling and root debridement. During the surgical treatment of the residual bone defects, first the supra-osseous granulation tissue samples will be collected. Afterwards, a flap will be raised, and the intra-osseous granulation tissue sample will be collected. Samples will be placed in Eppendorf tubes containing 100 µl of PBS (phosphate buffer saline, pH = 7.2) solution and will be stored at -80°C until laboratory analyses. Proteomics analysis - tissue samples will be homogenized in 100 mM ammonium bicarbonate (ABC) buffer in 2 ml reinforced tubes containing 2.8 mm ceramic (zirconium oxide) beads (Cayman Chemical) using Precellys Bead Mill Homogenizer (Bertin). Microbiome analysis - DNA will be extracted from tissue samples using the DNeasy Blood and Tissue kit following the manufacturer's recommendations (Qiagen, Germany) with minor modifications. Gel electrophoresis using Tapestation 2200 (Genomic DNA and D1000 screentapes, Agilent, USA) will be used to validate product size and purity of a subset of DNA extracts. DNA concentration will be measured using both Nanodrop and Qubit dsDNA BR Assay kit (Thermo Fisher Scientific, USA).

Targeted biochemical analysis - from all tissue samples proinflammatory (IL-1β, IL-6 and TNF-α) and anti-inflammatory (IL-4, IL-10) cytokines, macrophage-activation related chemokines (monocyte chemoattarctant protein C-C motif chemokine ligand 2 (CCL-2/MCP-1), C-C motif chemokine ligand 8 (CCL-8/ MCP-2), C-X-C motif chemokine ligand 9 (CXCL9/MIG), and C-C motif ligand 3 (CCL-3/MIP-1α)), and bone-remodeling marker (osteoprotegerin, Receptor activator of nuclear factor kappa-Β ligand (RANKL), osteocalcin, osteopontin) levels will be measured by Luminex and Simoa techniques, which can detect these markers at levels of femtogram/ml. Luminex 200 bead-based multiplex assay is available at the laboratories of Institute of Dentistry, University of Turku. Simoa HD-X analyzer is available at the laboratories of Turku University Central Hospital. Statistical analysis: Following the detection of the data distribution with the Kolmogorov-Smirnov test, repeated t-test or ANOVA in case of normal distribution will be used in the statistical analysis, and the Mann-Whitney U or Kruskal Wallis tests in case of non-normal distribution. In determining the correlation between healing and virulence marker correlations, the parametric Pearson test or the non-parametric Spearman test will be used according to the distribution. A binary logistic regression analysis with smoking, sex, and age adjustment will be conducted to assess the association between the analytes' levels and the healing response. P < 0.05 will be considered significant. Ethical approval for this project has been received from Riga Stradins University Research Ethics Committee on 28.02.2025. (2-PĒK-4/434/2025). Each patient will be informed about the research objectives and procedures both verbally and through a written informed consent form. They will be notified that, in accordance with patient protection laws, they have the right to withdraw from participation at any time. The patient will also be assured that withdrawing from the study will not affect their future treatment regimen with their periodontologist. Additionally, each patient will be informed that the data obtained during this research will be used to write publications in an anonymous and synthesized manner. All patient visits will be documented, and each patient will be assigned an anonymous patient number. Any necessary corrections to the medical documents will be made by crossing out the incorrect text with a single line and writing the correct text beside it. The clinician will sign next to the correction. If any side effects are observed during the study, the Ethics Committee will be notified.

Conditions

Periodontal Bone Loss; Periodontitis; Periodontal Disease; Periodontal Diseases; Periodontal Regeneration; Periodontal Granulation Tissue; Vertical Periodontal Bone Defects; Periodontal Healing

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Non-smoking periodontitis patients

Non-smoking Stage III-IV Grade B-C periodontitis patients with at least one infra-osseous approximal bone defect (with ≥3 mm infrabony component) at premolar-molar region (n=23).

No interventions assigned to this group

Smoking periodontitis patients

Smoking Stage III-IV Grade B-C periodontitis patients with at least one infra-osseous approximal bone defect (with ≥3 mm infrabony component) at premolar-molar region (n=23).

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Both genders.

2. Systemically healthy.

3. Both smokers (smoking at least 10 cigarettes a day or electronic cigarettes daily or quit less than 5 years ago) and non-smokers (never smoked, smoke no more than once a month or quit at least 5 years ago).

4. Patients aged 18 years and over.

5. Patients with a history of severe periodontitis (stage III or IV, grade B-C) and, after completion of the non-surgical stage of periodontal treatment with at least one residual vertical bone defects (with ≥3 mm infrabony component) in premolar-molar region.

6. Patients with a plaque index and bleeding on probing of 20% or lower before surgery.

Exclusion Criteria

1. Systemic diseases that may affect study results (uncontrolled type 2 diabetes mellitus (HBA1c level of >7%); recent (less than 6 months ago) myocardial infarction or stroke; blood coagulation disorders; recent use of antibiotics (less than 6 months).

2. Use of medications that may affect study results (anti-osteoporotic drugs, statins, corticosteroids, calcium channel blockers, cyclosporine A, antiepileptic drugs, antipsychotic medication or antidepressants, chemotherapy and/or radiotherapy (active or history)).

3. Current pregnancy and/or breastfeeding.

4. Patients who have received any form of systemic antibiotics in the last six months prior to the start of the study.

5. Patients who require antibiotic premedication prior to periodontal treatment.

6. Prosthetic factors in teeth associated with suitable bone defects that prevent clinical measurements.

7. Lack of patient motivation to undertake adequate dental care at home or to complete periodontal treatment.

8. Strong vomiting reflex preventing adequate periodontal treatment.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Turku

OTHER

Sponsor Role: collaborator

Riga Stradins University

OTHER

Sponsor Role: lead

Responsible Party

Dārta Elizabete Emuliņa

PhD student

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Riga Stradins University Institute of Stomatology

Riga, , Latvia

Site Status: RECRUITING

Countries

Latvia

Central Contacts

Dārta E Emuliņa, DDS

Role: CONTACT

dartaemulina@gmail.com

+37122007988

Facility Contacts

Dārta E Emuliņa, DDS

Role: primary

dartaemulina@gmail.com

+37122007988

Other Identifiers

2-PĒK-4/434/2025

Identifier Type: -

Identifier Source: org_study_id